Patents by Inventor Tetsuya Yamagata

Tetsuya Yamagata has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20230323456
    Abstract: A polynucleotide, comprising the following base sequences: (a) a base sequence encoding a fusion protein of a nuclease-deficient CRISPR effector protein and a transcription repressor, and (b) a base sequence encoding a guide RNA targeting a continuous region set forth in SEQ ID NO: 2, 3, 4, 20, 51, 68, 144, 148, 152, 162, 164, or 167 in the expression regulatory region of human DUX4 gene is expected to be useful for treating or preventing facioscapulohumeral muscular dystrophy (FSHD).
    Type: Application
    Filed: August 31, 2021
    Publication date: October 12, 2023
    Applicant: MODALIS THERAPEUTICS CORPORATION
    Inventors: Tetsuya YAMAGATA, Yuanbo QIN, Rebecca WINDMUELLER
  • Publication number: 20230279374
    Abstract: A mutant SaCas9 protein such as a protein having an amino acid sequence resulting from mutations of glutamic acid at the 782-position to lysine (E782K), leucine at the 800-position to arginine (L800R), asparagine at the 968-position to arginine (N968R), asparagine at the 985-position to alanine (N985A), arginine at the 991-position to alanine (R991A), alanine at the 1021-position to serine (A1021S), threonine at the 927-position to lysine (T927K), lysine at the 929-position to asparagine (K929N), and isoleucine at the 1017-position to phenylalanine (I1017F) in SEQ ID NO: 2 has relaxed restriction on target sequence while maintaining binding ability to guide RNA, and is useful as a tool for gene editing.
    Type: Application
    Filed: November 25, 2022
    Publication date: September 7, 2023
    Applicants: THE UNIVERSITY OF TOKYO, MODALIS THERAPEUTICS CORPORATION
    Inventors: Osamu NUREKI, Hiroshi NISHIMASU, Hisato HIRANO, Shohei KAJIMOTO, Tetsuya YAMAGATA, Yuanbo QIN, Keith M. CONNOLLY, Iain THOMPSON
  • Publication number: 20230248810
    Abstract: A polynucleotide, comprising the following base sequences: (a) a base sequence encoding a fusion protein of a nuclease-deficient CRISPR effector protein and a transcription repressor, and (b) a base sequence encoding a guide RNA targeting a continuous region of 18 to 24 nucleotides in length in a region set forth in SEQ ID NO: 54, 55, 56, 57, 68, 153 or 97 in the expression regulatory region of human MAPT gene. are expected to be useful for treating or preventing tauopathy including Alzheimer's disease.
    Type: Application
    Filed: July 9, 2021
    Publication date: August 10, 2023
    Applicant: Modalis Therapeutics Corporation
    Inventors: Iain Robert THOMPSON, Tetsuya YAMAGATA, Talha AKBULUT
  • Publication number: 20230173036
    Abstract: The present invention aims to provide a novel therapeutic approach to human muscular dystrophy (particularly MDC1A). The present invention provide a polynucleotide comprising the following base sequences: (a) a base sequence encoding a fusion protein of a nuclease-deficient CRISPR effector protein and a transcription activator, and (b) abase sequence encoding (i) a guide RNA targeting continuous region set forth in SEQ ID NO: 15, 20, 25, 50, 56, or 61, (ii) a guide RNA targeting a continuous region set forth in SEQ ID NO: 124, or (iii) a guide RNA targeting a continuous region set forth in SEQ ID NO: 178, 193, or 195, in the expression regulatory region of human LAMA1 gene.
    Type: Application
    Filed: August 14, 2020
    Publication date: June 8, 2023
    Applicant: Modalis Therapeutics Corporation
    Inventors: Yuanbo QIN, Tetsuya YAMAGATA
  • Patent number: 11591621
    Abstract: The present invention provides a method of treating a disease associated with elevated KRAS activity or expression in a subject, comprising suppressing KRAS expression in the subject by targeting an expression regulatory region of KRAS gene using a CRISPR-Guide Nucleotide Directed Modulation (GNDM). Also, provided is a CRISPR-GNDM system for suppressing KRAS expression comprising (a) a protein selected from the group consisting of dCas9 or dCpf1, a fusion protein of dCas9 or dCpf1 and Kruppel associated box (KRAB), and (b) a guide nucleotide targeting an expression regulatory region of KRAS gene.
    Type: Grant
    Filed: February 7, 2018
    Date of Patent: February 28, 2023
    Assignee: Modalis Therapeutics Corporation
    Inventors: Tetsuya Yamagata, Yuanbo Qin, Haruhiko Morita, Talha Akbulut, Iain Robert Thompson
  • Patent number: 11530396
    Abstract: A mutant SaCas9 protein such as a protein having an amino acid sequence resulting from mutations of glutamic acid at the 782-position to lysine (E782K), leucine at the 800-position to arginine (L800R), asparagine at the 968-position to arginine (N968R), asparagine at the 985-position to alanine (N985A), arginine at the 991-position to alanine (R991A), alanine at the 1021-position to serine (A1021S), threonine at the 927-position to lysine (T927K), lysine at the 929-position to asparagine (K929N), and isoleucine at the 1017-position to phenylalanine (I1017F) in SEQ ID NO: 2 has relaxed restriction on target sequence while maintaining binding ability to guide RNA, and is useful as a tool for gene editing.
    Type: Grant
    Filed: September 5, 2018
    Date of Patent: December 20, 2022
    Assignees: THE UNIVERSITY OF TOKYO, MODALIS THERAPEUTICS CORPORATION
    Inventors: Osamu Nureki, Hiroshi Nishimasu, Hisato Hirano, Shohei Kajimoto, Tetsuya Yamagata, Yuanbo Qin, Keith M. Connolly, Iain Thompson
  • Patent number: 11473071
    Abstract: Polynucleotides comprising the following base sequences: (a) a base sequence encoding a fusion protein of a nuclease-deficient CRISPR effector protein and a transcription activator, and (b) a base sequence encoding a guide RNA targeting a continuous region of 18 to 24 nucleotides in length in a region set forth in SEQ ID NO: 104, 105, 135, 141, 153, 167, or 172 in the expression regulatory region of human Utrophin gene are expected to be useful for treating or preventing DUCHENNE muscular dystrophy or BECKER muscular dystrophy.
    Type: Grant
    Filed: May 14, 2021
    Date of Patent: October 18, 2022
    Assignees: ASTELLAS PHARMA INC., MODALIS THERAPEUTICS CORPORATION
    Inventors: Eiji Yoshimi, Katsuro Yoshioka, Tetsuya Yamagata, Yuanbo Qin, Iain Robert Thompson, Nidhi Khanna
  • Patent number: 11439692
    Abstract: The present invention provides a method of treating a disease associated with activated MYD88 signaling in a subject, including suppressing MYD88 expression in a subject by targeting an expression regulatory region of MYD88 gene by using a CRISPR-Guide Nucleotide Directed Modulation (GNDM), without affecting the expression of an adjacent ACAA1 gene. Also, provided is a CRISPR-GNDM system for suppressing MYD88, including expression comprising (a) a protein selected from the group consisting of dCas9 or dCpf1, a fusion protein of dCas9 or dCpf1 and Kruppel associated box (KRAB) and (b) a guide RNA (gRNA) targeting an expression regulatory region of MYD88 gene.
    Type: Grant
    Filed: May 17, 2018
    Date of Patent: September 13, 2022
    Assignee: Modalis Therapeutics Corporation
    Inventors: Tetsuya Yamagata, Yuanbo Qin, Iain Robert Thompson, Haruhiko Morita
  • Publication number: 20220233721
    Abstract: Polynucleotides comprising the following base sequences: (a) a base sequence encoding a fusion protein of a nuclease-deficient CRISPR effector protein and a transcriptional repressor, and (b) a base sequence encoding a guide RNA targeting a continuous region of 18 to 24 nucleotides in length in a region set forth in SEQ ID NO: 127, SEQ ID NO: 46, SEQ ID NO: 128, SEQ ID NO: 129, SEQ ID NO: 130, SEQ ID NO: 131, SEQ ID NO: 132, SEQ ID NO: 88, SEQ ID NO: 91, SEQ ID NO: 133, SEQ ID NO: 137, SEQ ID NO: 117, or SEQ ID NO: 119 in an expression regulatory region of a human DMPK gene, are expected to be useful for treating muscular dystrophy.
    Type: Application
    Filed: May 27, 2020
    Publication date: July 28, 2022
    Applicants: Astellas Pharma Inc., Modalis Therapeutics Corporation
    Inventors: Eiji YOSHIMI, Tomoya OE, Tetsuya YAMAGATA, Keith M. CONNOLLY
  • Publication number: 20220017881
    Abstract: A protein having a binding ability to guide RNA and consisting of a sequence containing an amino acid sequence wherein a continuous deletion region is present between the 481-position and the 649-position in the amino acid sequence shown in SEQ ID NO: 2, the deletion region containing (i) all or a part of L1 domain (481- to 519-positions), and (ii) entire HNH domain (520- to 628-positions), and further optionally containing (iii) all or a part of L2 domain (629- to 649-positions), wherein amino acids adjacent to each of the deletion region are linked by a linker consisting of 3 to 10 amino acid residues functions as a miniaturized dSaCas9 protein while maintaining DNA binding affinity. Use of the miniaturized dSaCas9 protein makes it possible to mount many genes into vectors.
    Type: Application
    Filed: June 7, 2019
    Publication date: January 20, 2022
    Applicant: MODALIS THERAPEUTICS CORPORATION
    Inventors: Tetsuya YAMAGATA, Yuanbo QIN
  • Publication number: 20210355464
    Abstract: Polynucleotides comprising the following base sequences: (a) a base sequence encoding a fusion protein of a nuclease-deficient CRISPR effector protein and a transcription activator, and (b) a base sequence encoding a guide RNA targeting a continuous region of 18 to 24 nucleotides in length in a region set forth in SEQ ID NO: 104, 105, 135, 141, 153, 167, or 172 in the expression regulatory region of human Utrophin gene are expected to be useful for treating or preventing DUCHENNE muscular dystrophy or BECKER muscular dystrophy.
    Type: Application
    Filed: May 14, 2021
    Publication date: November 18, 2021
    Applicants: ASTELLAS PHARMA INC., MODALIS THERAPEUTICS CORPORATION
    Inventors: Eiji YOSHIMI, Katsuro YOSHIOKA, Tetsuya YAMAGATA, Yuanbo QIN, Iain Robert THOMPSON, Nidhi KHANNA
  • Publication number: 20210332094
    Abstract: The present invention provides a transcription activator consisting of not more than 200 amino acid sequences and containing VP64 and a transcription activation site of RTA. The present invention also provides a complex of a nucleic acid sequence-recognizing module specifically binding to a target nucleotide sequence in a double-stranded DNA and the transcription activator.
    Type: Application
    Filed: August 6, 2019
    Publication date: October 28, 2021
    Applicant: MODALIS THERAPEUTICS CORPORATION
    Inventors: Tetsuya YAMAGATA, Yuanbo QIN
  • Publication number: 20210260170
    Abstract: The present invention provides a method of treating a disease associated with activated MYD88 signaling in a subject, including suppressing MYD88 expression in a subject by targeting an expression regulatory region of MYD88 gene by using a CRISPR-Guide Nucleotide Directed Modulation (GNDM), without affecting the expression of an adjacent ACAA1 gene. Also, provided is a CRISPR-GNDM system for suppressing MYD88, including expression comprising (a) a protein selected from the group consisting of dCas9 or dCpf1, a fusion protein of dCas9 or dCpf1 and Kruppel associated box (KRAB) and (b) a guide RNA (gRNA) targeting an expression regulatory region of MYD88 gene.
    Type: Application
    Filed: May 17, 2018
    Publication date: August 26, 2021
    Inventors: Tetsuya YAMAGATA, Yuanbo QIN, lain Robert THOMPSON, Haruhiko MORITA
  • Publication number: 20210163907
    Abstract: A mutant SaCas9 protein such as a protein having an amino acid sequence resulting from mutations of glutamic acid at the 782-position to lysine (E782K), leucine at the 800-position to arginine (L800R), asparagine at the 968-position to arginine (N968R), asparagine at the 985-position to alanine (N985A), arginine at the 991-position to alanine (R991A), alanine at the 1021-position to serine (A1021S), threonine at the 927-position to lysine (T927K), lysine at the 929-position to asparagine (K929N), and isoleucine at the 1017-position to phenylalanine (I1017F) in SEQ ID NO: 2 has relaxed restriction on target sequence while maintaining binding ability to guide RNA, and is useful as a tool for gene editing.
    Type: Application
    Filed: September 5, 2018
    Publication date: June 3, 2021
    Applicants: THE UNIVERSITY OF TOKYO, MODALIS THERAPEUTICS CORPORATION
    Inventors: Osamu NUREKI, Hiroshi NISHIMASU, Hisato HIRANO, Shohei KAJIMOTO, Tetsuya YAMAGATA, Yuanbo QIN, Keith M. CONNOLLY, Iain THOMPSON
  • Publication number: 20190376088
    Abstract: The present invention provides a method of treating a disease associated with elevated KRAS activity or expression in a subject, comprising suppressing KRAS expression in the subject by targeting an expression regulatory region of KRAS gene using a CRISPR-Guide Nucleotide Directed Modulation (GNDM). Also, provided is a CRISPR-GNDM system for suppressing KRAS expression comprising (a) a protein selected from the group consisting of dCas9 or dCpf1, a fusion protein of dCas9 or dCpf1 and Kruppel associated box (KRAB), and (b) a guide nucleotide targeting an expression regulatory region of KRAS gene.
    Type: Application
    Filed: February 7, 2018
    Publication date: December 12, 2019
    Applicant: EdiGENE Corporation
    Inventors: Tetsuya YAMAGATA, Yuanbo QIN, Haruhiko MORITA, Talha AKBULUT, lain Robert THOMPSON
  • Publication number: 20130149503
    Abstract: The present invention provides an intermediate film for laminated glass which allows, in a laminated glass, improvement in penetration resistance throughout the laminated glass, and a laminated glass including the intermediate film for laminated glass. In an intermediate film for laminated glass, a first end is thinner than a second end, and in the intermediate film for laminated glass, a thin region has a moisture content higher than a moisture content of the thick region; and a laminated glass includes a first component for laminated glass, a second component for laminated glass, and an intermediate film sandwiched between the first component for laminated glass and the second component for laminated glass.
    Type: Application
    Filed: September 1, 2011
    Publication date: June 13, 2013
    Inventors: Satoru Yamamoto, Takeshi Yoshida, Daishun Fukui, Tetsuya Yamagata
  • Patent number: 6974620
    Abstract: A polyester film for use in a capacitor having high heat resistance, which consists of a biaxially oriented film containing a polyester (A) as a main component and a polyimide (B) and has a glass transition temperature of 105° C. to 145° C. and an elongation at break in the machine direction of 70% to 150%, offers a high glass transition temperature and excellent insulation volume resistance and insulation breakdown voltage at high ambient temperatures. This film can produce a metallized film for use in a capacitor having high heat resistance and also a film capacitor having high heat resistance.
    Type: Grant
    Filed: February 14, 2000
    Date of Patent: December 13, 2005
    Assignee: Toray Industries, Inc.
    Inventors: Tetsuya Tsunekawa, Masayoshi Asakura, Tetsuya Yamagata
  • Patent number: 4455146
    Abstract: A novel plaster comprising a thermoplastic elastomer, an oil or higher fatty acid, a tack-providing resin and a medicinal ingredient. The plaster may be easily released therefrom without giving appreciable irritation or pain to the skin and body hairs of human bodies after applied thereto, while it may nevertheless exhibit satisfactory tackiness and adhesive strength when applied to human bodies.
    Type: Grant
    Filed: March 2, 1982
    Date of Patent: June 19, 1984
    Assignee: Hisamitsu Pharmaceutical Co., Ltd.
    Inventors: Kanji Noda, Akira Nakagawa, Tetsuya Yamagata, Masasi Kobayasi, Tadayoshi Suenaga, Fumiaki Tokubuchi, Kazuki Noguchi, Tadaaki Yoshitake, Masayoshi Tsuji, Hiroyuki Ide
  • Patent number: 4393076
    Abstract: An anti-inflammatory analgesic gel composition comprising (1) ketoprofen and/or flurbiprofen as the effective ingredient, as well as (2) a glycol, lower alcohol, water and/or a mixture of a lower alcohol with water, (3) a gel-forming agent and, if desired, (4) a solubilizing agent and/or non-ionic surface-active agent as the ingredients of a gel base for the gel composition.
    Type: Grant
    Filed: February 16, 1982
    Date of Patent: July 12, 1983
    Assignee: Hisamitsu Pharmaceutical Co., Inc.
    Inventors: Kanji Noda, Akira Nakagawa, Tetsuya Yamagata, Hiroyuki Ide
  • Patent number: 4205685
    Abstract: A thermogenic sheet combined poultice comprising a thermogenic composition layer capable of generating heat in the presence of air or oxygen and a heat-stable wet pack composition layer; and a process for the production of the thermogenic sheet combined poultice.
    Type: Grant
    Filed: October 4, 1977
    Date of Patent: June 3, 1980
    Assignees: Hisamitsu Pharmaceutical Co., Ltd., Toyo Ink Manufacturing Co., Ltd.
    Inventors: Risaburo Yoshida, Keisuke Kaiho, Yusaku Ide, Kanji Noda, Tetsuya Yamagata, Hirotaka Kida